Low-Dose Naltrexone Presents New Options for Patients with Inflammatory, Autoimmune Diseases

Video

Sebastian Denison, RPh, BScPharm, said new developments are constantly being published for the use of low-dose naltrexone in patients with inflammatory and autoimmune diseases.

In an interview at the Pharmacy Development Services 2022 conference, Sebastian Denison, RPh, BScPharm, said new developments are constantly being published for the use of low-dose naltrexone in patients with inflammatory and autoimmune diseases.

Traditionally used for patients with alcoholism or other forms of addiction, Denison said there is a growing body of case studies and research into the use of naltrexone for other treatments. Whereas the patented dosage is a 50 mg capsule, research is ongoing into the use of much smaller dosages. Denison also discussed the mechanism of action for naltrexone, how the evidence for naltrexone may differ from other bodies of research, and some adverse events that pharmacists should be aware of.

Related Videos
BillionPhotos.com - stock.adobe.com
Whole psilocybin mushroom in a clear medication capsule | Image credit: Zim - stock.adobe.com
Patient suffering from atopic dermatitis -- Image credit: Nikkikii | stock.adobe.com
Image credit: Fabio Balbi | stock.adobe.com
Image credit: Melita - stock.adobe.com
Atopic dermatitis on a patient's hand -- Image credit: Ольга Тернавская | stock.adobe.com
cropped view of man performing chest compression on dummy during cpr training class - Image credit: LIGHTFIELD STUDIOS | stock.adobe.com
Medicine law concept. Judges gavel with pills | Image Credit: Iren Moroz - stock.adobe.com
Image credit: New Africa | stock.adobe.com
© 2024 MJH Life Sciences

All rights reserved.